281 related articles for article (PubMed ID: 21276940)
1. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.
Fedorov O; Huber K; Eisenreich A; Filippakopoulos P; King O; Bullock AN; Szklarczyk D; Jensen LJ; Fabbro D; Trappe J; Rauch U; Bracher F; Knapp S
Chem Biol; 2011 Jan; 18(1):67-76. PubMed ID: 21276940
[TBL] [Abstract][Full Text] [Related]
2. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
[TBL] [Abstract][Full Text] [Related]
3. Regulation of influenza A virus mRNA splicing by CLK1.
Artarini A; Meyer M; Shin YJ; Huber K; Hilz N; Bracher F; Eros D; Orfi L; Keri G; Goedert S; Neuenschwander M; von Kries J; Domovich-Eisenberg Y; Dekel N; Szabadkai I; Lebendiker M; Horváth Z; Danieli T; Livnah O; Moncorgé O; Frise R; Barclay W; Meyer TF; Karlas A
Antiviral Res; 2019 Aug; 168():187-196. PubMed ID: 31176694
[TBL] [Abstract][Full Text] [Related]
4. Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells.
Eisenreich A; Bogdanov VY; Zakrzewicz A; Pries A; Antoniak S; Poller W; Schultheiss HP; Rauch U
Circ Res; 2009 Mar; 104(5):589-99. PubMed ID: 19168442
[TBL] [Abstract][Full Text] [Related]
5. Clk/STY (cdc2-like kinase 1) and Akt regulate alternative splicing and adipogenesis in 3T3-L1 pre-adipocytes.
Li P; Carter G; Romero J; Gower KM; Watson J; Patel NA; Cooper DR
PLoS One; 2013; 8(1):e53268. PubMed ID: 23308182
[TBL] [Abstract][Full Text] [Related]
6. Role of the phosphatidylinositol 3-kinase/protein kinase B pathway in regulating alternative splicing of tissue factor mRNA in human endothelial cells.
Eisenreich A; Malz R; Pepke W; Ayral Y; Poller W; Schultheiss HP; Rauch U
Circ J; 2009 Sep; 73(9):1746-52. PubMed ID: 19597299
[TBL] [Abstract][Full Text] [Related]
7. CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.
Funnell T; Tasaki S; Oloumi A; Araki S; Kong E; Yap D; Nakayama Y; Hughes CS; Cheng SG; Tozaki H; Iwatani M; Sasaki S; Ohashi T; Miyazaki T; Morishita N; Morishita D; Ogasawara-Shimizu M; Ohori M; Nakao S; Karashima M; Sano M; Murai A; Nomura T; Uchiyama N; Kawamoto T; Hara R; Nakanishi O; Shumansky K; Rosner J; Wan A; McKinney S; Morin GB; Nakanishi A; Shah S; Toyoshiba H; Aparicio S
Nat Commun; 2017 Feb; 8(1):7. PubMed ID: 28232751
[TBL] [Abstract][Full Text] [Related]
8. Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCbetaII messenger ribonucleic acid.
Jiang K; Patel NA; Watson JE; Apostolatos H; Kleiman E; Hanson O; Hagiwara M; Cooper DR
Endocrinology; 2009 May; 150(5):2087-97. PubMed ID: 19116344
[TBL] [Abstract][Full Text] [Related]
9. Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation.
Bullock AN; Das S; Debreczeni JE; Rellos P; Fedorov O; Niesen FH; Guo K; Papagrigoriou E; Amos AL; Cho S; Turk BE; Ghosh G; Knapp S
Structure; 2009 Mar; 17(3):352-62. PubMed ID: 19278650
[TBL] [Abstract][Full Text] [Related]
10. Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945.
Lee JY; Yun JS; Kim WK; Chun HS; Jin H; Cho S; Chang JH
Biomed Res Int; 2019; 2019():6125068. PubMed ID: 31531359
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
Mott BT; Tanega C; Shen M; Maloney DJ; Shinn P; Leister W; Marugan JJ; Inglese J; Austin CP; Misteli T; Auld DS; Thomas CJ
Bioorg Med Chem Lett; 2009 Dec; 19(23):6700-5. PubMed ID: 19837585
[TBL] [Abstract][Full Text] [Related]
12. Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.
Murár M; Dobiaš J; Šramel P; Addová G; Hanquet G; Boháč A
Eur J Med Chem; 2017 Jan; 126():754-761. PubMed ID: 27940419
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing.
Araki S; Dairiki R; Nakayama Y; Murai A; Miyashita R; Iwatani M; Nomura T; Nakanishi O
PLoS One; 2015; 10(1):e0116929. PubMed ID: 25581376
[TBL] [Abstract][Full Text] [Related]
14. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.
Debdab M; Carreaux F; Renault S; Soundararajan M; Fedorov O; Filippakopoulos P; Lozach O; Babault L; Tahtouh T; Baratte B; Ogawa Y; Hagiwara M; Eisenreich A; Rauch U; Knapp S; Meijer L; Bazureau JP
J Med Chem; 2011 Jun; 54(12):4172-86. PubMed ID: 21615147
[TBL] [Abstract][Full Text] [Related]
15. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion.
Liu Y; Conaway L; Rutherford Bethard J; Al-Ayoubi AM; Thompson Bradley A; Zheng H; Weed SA; Eblen ST
Nucleic Acids Res; 2013 May; 41(9):4949-62. PubMed ID: 23519612
[TBL] [Abstract][Full Text] [Related]
17. Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.
Walter A; Chaikuad A; Helmer R; Loaëc N; Preu L; Ott I; Knapp S; Meijer L; Kunick C
PLoS One; 2018; 13(5):e0196761. PubMed ID: 29723265
[TBL] [Abstract][Full Text] [Related]
18. Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A.
Yomoda J; Muraki M; Kataoka N; Hosoya T; Suzuki M; Hagiwara M; Kimura H
Genes Cells; 2008 Mar; 13(3):233-44. PubMed ID: 18298798
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells.
Bowler E; Porazinski S; Uzor S; Thibault P; Durand M; Lapointe E; Rouschop KMA; Hancock J; Wilson I; Ladomery M
BMC Cancer; 2018 Apr; 18(1):355. PubMed ID: 29606096
[TBL] [Abstract][Full Text] [Related]
20. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).
Rosenthal AS; Tanega C; Shen M; Mott BT; Bougie JM; Nguyen DT; Misteli T; Auld DS; Maloney DJ; Thomas CJ
Bioorg Med Chem Lett; 2011 May; 21(10):3152-8. PubMed ID: 21450467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]